1-20 of 623 Search Results for

glp-1-glucagon-peptide-1-0

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):57-OR
Published: 01 June 2019
...; TRICIA M.M. TAN Background: Roux-en-Y gastric bypass (RYGB) is a successful treatment for diabetes and obesity, possibly because it augments post-prandial secretion of the gut hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM) and peptide YY (PYY). Subcutaneous infusion of GLP-1, OXM and PYY...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1118-P
Published: 01 July 2018
...TAKAHIRO KAWAI; FUMIHITO TANINO; MASANORI FUKAZAWA; KOTARO OGAWA; SHUNSUKE NAGAO; HITOSHI YOSHINO; SHUN-ICHIRO KOMATSU; YOSHIYUKI SUZUKI; YOSHIKI KAWABE Activation of glucagon-like peptide-1 receptors (GLP-1R) is a promising approach for the treatment of type 2 diabetes mellitus (T2D), and several...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):981-P
Published: 01 June 2019
... control. In a randomized, double-blinded, cross-over study, we evaluated the insulinotropic effect of exogenous glucose-dependent insulinotropic peptide (GIP) and glucagon-like-peptide 1 (GLP-1), respectively, with and without SU in patients with HNF1A-diabetes. Ten patients with HNF1A-diabetes ([mean±SD...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1839-P
Published: 01 June 2019
...MARIA D. HURTADO; AOIFE M. EGAN; MARCELLO C. LAURENTI; J.D. ADAMS; ROBERT A. RIZZA; CLAUDIO COBELLI; ALEKSEY MATVEYENKO; CHIARA DALLA MAN; ADRIAN VELLA Glucagon-Like Peptide-1 (GLP-1) potentiates insulin secretion in response to an oral challenge. Exendin-(9,39) a competitive antagonist of GLP-1...
Images
Plasma concentrations of <span class="search-highlight">GLP</span>-<span class="search-highlight">1</span> (<em>A</em>), glucose (<em>C</em>...
Published: 23 April 2011
FIG. 1. Plasma concentrations of GLP-1 (A), glucose (C), insulin (D), glucagon (E), C-peptide (F), PP (G), and GIP (H), and gastric emptying (B) after instilling two liquid test meals (amino acids and sucrose) via a nasogastric tube into the stomach at 0 and 240 min in nine healthy young volunteers during the intravenous infusion of GLP-1 (0.8 pmol · kg−1 ⋅ min−1) or placebo. Mean ± SEM. P values were calculated by repeated-measures ANOVA. *Significant (P < 0.05) differences at specific time points between experiments with placebo and GLP-1. †Significant difference from the corresponding time point after the first meal during the exogenous administration of GLP-1. FIG. 1. Plasma concentrations of GLP-1 (A), glucose (C), insulin (D), glucagon (E), C-peptide (F), PP (G), and GIP (H), and gastric emptying (B) after instilling two liquid test meals (amino acids and sucrose) via a nasogastric tube into the stomach at 0 and 240 min in nine healthy young volunteers during the intravenous infusion of GLP-1 (0.8 pmol · kg−1 ⋅ min−1) or placebo. Mean ± SEM. P values were calculated by repeated-measures ANOVA. *Significant (P < 0.05) differences at specific time points between experiments with placebo and GLP-1. †Significant difference from the corresponding time point after the first meal during the exogenous administration of GLP-1. More
Journal Articles
Journal: Diabetes
Diabetes 2019;68(5):906–917
Published: 09 January 2019
... glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes...
Journal Articles
Journal: Diabetes
Diabetes 2005;54(7):2212–2218
Published: 01 July 2005
... in addition to GLP-1. A liquid test meal (50 g sucrose and 8% mixed amino acids in 400 ml) was administered at 0 min. Capillary and venous blood samples were drawn for the determination of glucose (glucose oxidase), insulin, C-peptide, GLP-1, glucagon, gastric inhibitory polypeptide (GIP), and pancreatic...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1539-P
Published: 01 June 2019
...-matched to patients newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist. The primary outcome was lower-limb amputation requiring surgery. Hazard ratios (HR) and 95% confidence intervals (CI) were computed for the risk of subsequent amputation among patients <65 and ≥65 years old. We...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1961-P
Published: 01 July 2018
... responses were ∼25% greater in the OGTT compared to the other treatments, whereas there was <5% difference in their levels in Po vs. Pe. Arterial glucagon fell modestly in all treatments. Oral glucose administration increased arterial GLP-1 and GIP levels by >6-fold over basal, but their levels did...
Journal Articles
Journal: Diabetes
Diabetes 1995;44(6):626–630
Published: 01 June 1995
.... Paul Williamson, Pamela Zabel, and Thomas J. McDonald Effects of human glucagon-like peptide I (GLP-I)(7- 36)amide were examined in volunteers having insulin- Gdependent diabetes mellitus (IDDM) with residual C-peptide (CP) secretion (« = 8,7 men and 1 woman; age, astric inhibitory polypeptide (GIP...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):72-OR
Published: 01 July 2018
...BRITTA GOEBEL; MICHELE SCHIAVON; ROBERTO VISENTIN; MICHELA RIZ; CHIARA DALLA MAN; CLAUDIO COBELLI; THOMAS KLABUNDE SAR425899 (SAR) is a novel dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. A randomized, double-blind, phase I multiple-ascending-dose study (NCT02411825...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):755-P
Published: 01 June 2019
... secretion in participants with type 2 diabetes (T2D). Research Design and Methods: A randomized crossover design was used in 20 participants with T2D. Plasma concentrations of glucose, insulin, C-peptide, glucagon-like peptide -1 (GLP-1), amylin, and gastric inhibitory peptide (GIP) were determined at 0...
Meeting Abstracts
Journal: Diabetes
Diabetes 2020;69(Supplement_1):931-P
Published: 01 June 2020
... of optimal treatment choice, comparing intensification with additional oral antidiabetic drug (OAD), glucagon-like peptide-1 (GLP-1) analogs or insulin in individuals on 2 OADs. Methods: Electronic medical records and claims data were from IBM MarketScan Explorys Claims-EMR (index period: 3/1/13-10/31/18...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1969-P
Published: 01 June 2019
...TAKAAKI MURAKAMI; HIROYUKI FUJIMOTO; NAOTAKA FUJITA; KEITA HAMAMATSU; JUNJI FUJIKURA; NOBUYA INAGAKI Aims: For the purpose of visualization and quantification of β cells, glucagon-like peptide 1 receptor (GLP-1R)-targeting imaging including single photon emission computed and positron emission...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1326-P
Published: 01 June 2019
.... Recent data suggests a primary role for the entero-insular instead of the gluconeogenic pathway, but there is no data in youth, in whom metformin efficacy is ∼50%. Our objectives were to: (1) compare incretin concentrations, glucagon-like 1 peptide (GLP-1) and gastric inhibitory polypeptide (GIP) in 12...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1086-P
Published: 01 July 2018
...LANA C. PINTO; DIMITRIS V. RADOS; MARIANA R. FALCETTA; CRISTIANE B. LEITAO Background: Glucagon-like peptide-1 (GLP-1) receptors were identified in both acinar and ductal cells of pancreas. Animal studies suggested an association of GLP-1 agonists use and pancreatic premalignant changes. Randomized...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1033-P
Published: 01 June 2019
...JINGYAN CHEN; QIN SUN; MIN ZHANG; HAOMING TIAN; SHU CHEN Objective: Polycystic ovary syndrome (PCOS) is one the most common metabolic and endocrine disorders in women, which is always accompanied with obesity and insulin resistance (IR). Glucagon-like peptide-1 (GLP-1) has been investigated...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):414-P
Published: 01 July 2018
...OSAMAH ALFAYEZ; MAJED S. AL YAMI; RAZAN ALSHEIKH Background: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) was recently published. Thus, we here present a mixed treatment comparison meta-analysis (MTC) of major randomized clinical trials to determine Glucagon like peptide 1 (GLP-1...
Journal Articles
Journal: Diabetes
Diabetes 1993;42(5):658–661
Published: 01 May 1993
...- bolic clearance rates of the two peptides. The effects of GLP-1 7-36 amide and GLP-1 7-37 on FIG. 2. Plasma concentrations of glucose (A), C-peptide (B), insulin 60 120 180 min (C), and glucagon (0) before, during, and after Intravenous Infusion of either GLP-1 7-36 amide ( ) or GLP-1 7-37 ( ). Mean...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1914-P
Published: 01 June 2019
... participants (O, n=20), and healthy controls (H, n=20). Plasma concentrations of glucagon-like peptide -1 (GLP-1), amylin, and peptide YY (PYY) were determined at 0, 30, 60, 120 and 180 minutes. Satiety was assessed using a visual analogue scale. Repeated-measures ANOVA was used for statistical analysis...